Caidya, a US-based global provider of clinical trial solutions, announced on Monday that it has named Barbara Lopez Kunz as its new chief executive officer, effective 1 September 2024.

In the new role, Kunz is to concentrate on improving the company's position as a global leader in clinical research, emphasising the importance of patient-centred trials and building personalised, fit-for-purpose solutions.

Kunz is a member of the Caidya board of directors. She has a range of experience and has worked in various leadership capacities across the healthcare and life sciences sectors. She has more than 15 years of C-suite experience and a proven track record in driving strategic partnerships and digital transformation. She has held significant P&L responsibilities at major companies including Thermo Fisher Scientific, DuPont, and ICI (now AstraZeneca), as well as at non-profits like Battelle and DIA.